Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

AIMS: To validate and improve the existing algorithm (proposed by Hans et al.) to classify diffuse large B-cell lymphoma (DLBCL). METHODS AND RESULTS: Tissue microarrays constructed from 81 patients with DLBCL were studied by immunohistochemistry for expression of CD10, Bcl-6, MUM1, Bcl-2, cyclin-D2, FOXP1 and PKC-gamma proteins. Cases were classified as either germinal centre B-like (GCB) or non-GC according to Hans et al. An alternative classification was also employed, in which cases positive for either CD10 or Bcl-6 were considered as a GC subgroup and cases negative for both CD10 and Bcl-6 were considered as a non-GC subgroup. GC was further subdivided into favourable GC (negative for both Bcl-2 and cyclin-D2) and unfavourable GC (positive for either Bcl-2 or cyclin-D2). The 5-year event-free survival (EFS) amongst patients classified as favourable GC versus 'others' was 49.5% and 7.3%, respectively (log rank P < 0.0001). Similarly, the 5-year overall survival (OS) amongst patients classified as favourable GC versus 'others' was 58.6% and 13.7%, respectively (log rank P = 0.0001). The difference in survival was independent of the international prognostic index. CONCLUSIONS: In this group of patients the risk stratification based on the new algorithm was better than that proposed by Hans et al.

Original publication

DOI

10.1111/j.1365-2559.2007.02721.x

Type

Journal article

Journal

Histopathology

Publication Date

07/2007

Volume

51

Pages

70 - 79

Keywords

Algorithms, Biomarkers, Tumor, Cyclin D2, Cyclins, Gene Expression Regulation, Neoplastic, Germinal Center, Humans, Kaplan-Meier Estimate, Lymphoma, Large B-Cell, Diffuse, Middle Aged, Neprilysin, Prognosis, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-bcl-6, Risk Factors